Comparative efficacy and safety of nalidixic acid versus trimethoprim/sulfamethoxazole in treatment of acute urinary tract infections in college-age women.

Antimicrobial Agents and Chemotherapy
A IravaniR Fennell

Abstract

One hundred and thirty-five college-age women with acute urinary tract infections caused by gram-negative Enterobacteriaceae were treated by random allocation with either nalidixic acid (NA), 1 g every 6 h for 7 days, or trimethoprim/sulfamethoxazole (TMP/SMZ), 160/800 mg every 12 h for 10 days. The clinical and bacteriological cure rates were 98.0% in each group on the last day of therapy. At 1 and 4 week posttherapy, both the clinical and bacteriological cure rates for NA declined to 90.0 and 74.0% respectively; for TMP/SMZ, they declined to 93.0 and 72.0% respectively. By 4 weeks posttherapy, 96.0% of the TMP/SMZ group and 93.0% of the NA group had remained free of the initial urinary pathogens. Neither drug was associated with emergence of resistant bacterial mutants in urine. The antibody-coated bacteria tested (ACBT) localized 31.5% of the infections of the kidney and 67.7% to the bladder. Upper tract symptoms did not correlate with the presence of a positive ACBT. The response to therapy was similar for the two regimens regardless of ACBT results. After treatment, the emergence of resistant Enterobacteriaceae in fecal flora was 1.1% in the NA group and 2.3% in the TMP/SMZ group. The incidences of drug reactions were 7.0%...Continue Reading

References

Apr 1, 1977·The Journal of Infectious Diseases·J W SmithB Kaijser
Sep 8, 1978·JAMA : the Journal of the American Medical Association·G K HardingP Muir
Apr 1, 1978·Journal of Clinical Pathology·W A GillespieA L Hilton
Oct 18, 1976·JAMA : the Journal of the American Medical Association·T A Stamey, J Bragonje
Jan 1, 1973·Scandinavian Journal of Urology and Nephrology·S T Madsen
Mar 14, 1974·The New England Journal of Medicine·V ThomasM Forland
Mar 14, 1974·The New England Journal of Medicine·S R JonesJ P Sanford
May 1, 1974·The Journal of Urology·M D Cosgrove, J W Morrow
Jan 1, 1974·Scandinavian Journal of Infectious Diseases·A CederbergI Juhlin
Nov 17, 1966·The New England Journal of Medicine·A R RonaldR G Petersdorf
Oct 1, 1980·The Journal of Infectious Diseases·P A JordanH Baer
Dec 1, 1958·Journal of Chronic Diseases·S J CUTLER, F EDERER
Sep 1, 1962·The Journal of Clinical Investigation·M TURCK, R G PETERSDORF
Sep 11, 1965·British Medical Journal·R M JAMESON

❮ Previous
Next ❯

Citations

Sep 1, 1992·Journal of General Internal Medicine·A G PinsonJ B Schorling
Oct 1, 1982·Antimicrobial Agents and Chemotherapy·A Iravani, G A Richard
Jan 4, 2017·Médecine et maladies infectieuses·F CaronM Etienne
Sep 1, 1983·The Journal of Urology·A IravaniG A Richard

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.